Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need / AskBio’s industry leading AAV-based gene therapy platform already yielding commercial and clinical stage assets with potential of helping larger patient populations / Portfolio includes investigational pre-clinical and clinical stage development candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases such as therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure, as well as out-licensed clinical candidates for hemophilia and Duchenne muscular dystrophy / Acquisition secures additionally revenue generating Contract Development and Manufacturing Business based on highly efficient Pro10™ Cell line / AskBio to operate autonomously and on an arms-length basis / Purchase price of USD 2 billion upfront and up to USD 2 billion in success-based milestone payments
Read More